Table 4 Engraftment of sorted ALL cell... | American Society of Hematology

Table 4

Engraftment of sorted ALL cell populations in serial recipients

ALL subfraction, NOD/SCID xenograft recipient	No. of cells injected	% CD45⁺ in BM	% FISH⁺	Immunophenotype*
CD34⁺/CD4⁻
Patient 2
Primary recipient	1 × 10⁵	88	—	CD2⁺/CD3⁻/CD4⁺/CD7⁺/CD8⁻/CD19⁻/CD33⁻
Secondary recipient	1 × 10⁵	94	—	CD2⁺/CD3⁻/CD4⁺/CD7⁺/CD8⁻/CD19⁻/CD33⁻
Tertiary recipient	1 × 10⁵	97	—	CD2⁺/CD3⁻/CD4⁺/CD7⁺/CD8⁻/CD19⁻/CD33⁻
Patient 6
Primary recipient	2 × 10⁴	22	98	CD2⁺/CD3⁻/CD4⁺/CD7⁺/CD8⁺/CD19⁻/CD33⁻
Secondary recipient	2 × 10⁴	19	100	CD2⁺/CD3⁻/CD4⁺/CD7⁺/CD8⁺/CD19⁻/CD33⁻
Patient 12
Primary recipient	1 × 10⁵	59	—	CD2⁺/CD3⁻/CD4⁻/CD7⁺/CD19⁻/CD33⁻/CD34⁺
Secondary recipient	1 × 10⁵	47	—	CD2⁺/CD3⁻/CD4⁻/CD7⁺/CD19⁻/CD33⁻/CD34⁺
Tertiary recipient	1 × 10⁵	55	—	CD2⁺/CD3⁻/CD4⁻/CD7⁺/CD19⁻/CD33⁻/CD34⁺
Patient 14
Primary recipient	3 × 10⁴	47	72	CD3⁻/CD4⁺/CD7⁺/CD19⁻/CD33⁻
Secondary recipient	3 × 10⁴	43	70	CD3⁻/CD4⁺/CD7⁺/CD19⁻/CD33⁻
CD34⁺/CD7⁻
Patient 6
Primary recipient	8 × 10⁴	4	100	CD2⁺/CD3⁻/CD4⁺/CD7⁺/CD8⁺/CD19⁻/CD33⁻
Secondary recipient	8 × 10⁴	5	100	CD2⁺/CD3⁻/CD4⁺/CD7⁺/CD8⁺/CD19⁻/CD33⁻
Patient 13
Primary recipient	1 × 10⁴	82	64	CD2⁺/CD3⁻/CD4⁺/CD7⁺/CD8⁻/CD19⁻/CD33⁻
Secondary recipient	1 × 10⁴	77	67	CD2⁺/CD3⁻/CD4⁺/CD7⁺/CD8⁻/CD19⁻/CD33⁻
Patient 14
Primary recipient	4 × 10³	80	80	CD3⁻/CD4⁺/CD7⁺/CD19⁻/CD33⁻
Secondary recipient	4 × 10³	67	100	CD3⁻/CD4⁺/CD7⁺/CD19⁻/CD33⁻
Patient 16
Primary recipient	2 × 10⁴	85	74	CD3⁻/CD4⁺/CD7⁺/CD19⁻/CD33⁻/CD34⁺
Secondary recipient	2 × 10⁴	82	69	CD3⁻/CD4⁺/CD7⁺/CD19⁻/CD33⁻/CD34⁺

ALL subfraction, NOD/SCID xenograft recipient	No. of cells injected	% CD45⁺ in BM	% FISH⁺	Immunophenotype*
CD34⁺/CD4⁻
Patient 2
Primary recipient	1 × 10⁵	88	—	CD2⁺/CD3⁻/CD4⁺/CD7⁺/CD8⁻/CD19⁻/CD33⁻
Secondary recipient	1 × 10⁵	94	—	CD2⁺/CD3⁻/CD4⁺/CD7⁺/CD8⁻/CD19⁻/CD33⁻
Tertiary recipient	1 × 10⁵	97	—	CD2⁺/CD3⁻/CD4⁺/CD7⁺/CD8⁻/CD19⁻/CD33⁻
Patient 6
Primary recipient	2 × 10⁴	22	98	CD2⁺/CD3⁻/CD4⁺/CD7⁺/CD8⁺/CD19⁻/CD33⁻
Secondary recipient	2 × 10⁴	19	100	CD2⁺/CD3⁻/CD4⁺/CD7⁺/CD8⁺/CD19⁻/CD33⁻
Patient 12
Primary recipient	1 × 10⁵	59	—	CD2⁺/CD3⁻/CD4⁻/CD7⁺/CD19⁻/CD33⁻/CD34⁺
Secondary recipient	1 × 10⁵	47	—	CD2⁺/CD3⁻/CD4⁻/CD7⁺/CD19⁻/CD33⁻/CD34⁺
Tertiary recipient	1 × 10⁵	55	—	CD2⁺/CD3⁻/CD4⁻/CD7⁺/CD19⁻/CD33⁻/CD34⁺
Patient 14
Primary recipient	3 × 10⁴	47	72	CD3⁻/CD4⁺/CD7⁺/CD19⁻/CD33⁻
Secondary recipient	3 × 10⁴	43	70	CD3⁻/CD4⁺/CD7⁺/CD19⁻/CD33⁻
CD34⁺/CD7⁻
Patient 6
Primary recipient	8 × 10⁴	4	100	CD2⁺/CD3⁻/CD4⁺/CD7⁺/CD8⁺/CD19⁻/CD33⁻
Secondary recipient	8 × 10⁴	5	100	CD2⁺/CD3⁻/CD4⁺/CD7⁺/CD8⁺/CD19⁻/CD33⁻
Patient 13
Primary recipient	1 × 10⁴	82	64	CD2⁺/CD3⁻/CD4⁺/CD7⁺/CD8⁻/CD19⁻/CD33⁻
Secondary recipient	1 × 10⁴	77	67	CD2⁺/CD3⁻/CD4⁺/CD7⁺/CD8⁻/CD19⁻/CD33⁻
Patient 14
Primary recipient	4 × 10³	80	80	CD3⁻/CD4⁺/CD7⁺/CD19⁻/CD33⁻
Secondary recipient	4 × 10³	67	100	CD3⁻/CD4⁺/CD7⁺/CD19⁻/CD33⁻
Patient 16
Primary recipient	2 × 10⁴	85	74	CD3⁻/CD4⁺/CD7⁺/CD19⁻/CD33⁻/CD34⁺
Secondary recipient	2 × 10⁴	82	69	CD3⁻/CD4⁺/CD7⁺/CD19⁻/CD33⁻/CD34⁺

— indicates not tested.

The cutoff for positivity was set at 20% of cells staining more intensely than the isotype control, in accordance with standard diagnostic immunophenotyping procedures defined by the British Committee for Standards in Haematology.²⁴

View Large

This Feature Is Available To Subscribers Only